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Abstract 
Hepatocellular carcinoma (HCC) is an aggressive and destructive cancer of the 
liver.  Currently available treatment plans are locoregional therapies aimed to decrease 
tumor burden, resection that surgically removes the tumor, or systemic therapies for 
advanced stage to extend survival.  However, decompensation post-locoregional 
treatment and recurrence rates for HCC remain high despite the different treatment 
modalities.  There is a great need for alternative and more effective treatment methods 
that will further dampen tumor burden while decreasing the risk of intra- and 
extrahepatic spread.  The goal of this project was to develop a non-invasive therapeutic 
treatment to target HCC cells using human serum albumin particles (HSAPs). 
In this study, nanoparticles were prepared using human serum albumin (HSA) 
and synthesized to house gold nanorods (AuNRs).  The AuNR-HSAPs were incubated 
with hepatic cell lines under different stresses of chemotherapy drug, doxorubicin, with 
near-infrared laser irradiation.  Metabolic activity and viability were determined via MTT 
assay and flow cytometry. 
  Particle uptake in HCC lines was confirmed.  AuNRs were sufficient to cause 
metabolic stress and reduce viability by 10-25% in a cell line dependent manner. The 
combination of AuNRs and laser irradiation did not significantly impact viability that 
differed from AuNRs alone in any of the cell lines tested, doxorubicin doses chosen 
were aimed to decrease viability by 10%. The combination of AuNRs, laser irradiation, 
and doxorubicin provided the largest decrease in viability.  However, it was not 
statistically significant from the control.  
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Introduction 
Hepatocellular carcinoma (HCC) is the most common form of liver malignancy, 
accounting for over 75% of all liver cancers.2  HCC arises due to underlying cirrhosis 
mainly caused by hepatitis viral infections, nonalcoholic steatohepatitis (NASH), or 
alcohol.  Each year, over 700,000 patients are diagnosed with HCC globally.1  As of 
2018, HCC is the third leading cause of cancer-related deaths worldwide.  As the 
curative rate of the hepatitis C virus continues to increase with advancements in 
medicine, HCC will continue to be a threat in the obesity epidemic with it developing in 
the background of NASH. 
The only curative treatment options available for patients with HCC are orthotopic 
liver transplantation (removal of the cancer and the underlying cirrhosis) and resection 
(partial removal of the liver reserved only for patients without cirrhosis).  Despite 
advances in medicine, the five-year survival rate for HCC remains low at approximately 
18%.17  Recurrence rates for HCC are higher for resected patients, ranging from 
approximately 50% to 70% for patients undergoing resection, while rates range from 20-
40% for transplanted patients.21  Organ shortage is a major issue, as it lengthens the 
patient waitlist time, allowing for tumor progression.  It also limits the number of patients 
able to receive a transplant.  To decrease tumor burden, locoregional therapy (LRT) is 
used while patients are on the transplant waitlist.  The main types of LRT include: 
microwave/thermal ablation; doxorubicin-eluting bead transarterial chemoembolization 
(DEB-TACE); or radioembolization.  While LRT has proven effective in some patients on 
eliminating tumors, LRT can also cause decompensation (acute liver failure) and 
intrahepatic tumor spread, likely from aggressive tumor biology.  Lastly, for patients with 
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advance-stage HCC, palliative systemic treatment remains the only treatment options.  
The drug, sorafenib, is widely used, but it only increases survival by a few months.3  
Thus, the development of alternative, more effective methods of care are necessary to 
combat HCC and eliminate the negative effects on surrounding non-cancerous tissue. 
The goal of this research project is to develop a non-invasive therapeutic treatment with 
diminished side effects impacting the patient. 
Human serum albumin nanoparticles (HSAPs) are prepared using the most 
abundant protein in the blood, human serum albumin (HSA).  The albumin is used as a 
carrier protein to assist in moving molecules into cells.  The nanoparticles are 
synthesized to form globular structures, which may be internally bound with 
chemotherapeutic drugs and/or gold nanorods (AuNRs) during particle synthesis.  The 
nanocomposites can be injected directly into the tumor site.  Enzymatic degradation of 
the HSAPs allow for the release of encapsulated drugs to attack the tumor. HSAP could 
also be combined with infrared laser irradiation that heats the AuNRs, thereby inducing 
apoptosis in cells through hyperthermal effects.  
The combinatorial use of the gold-loaded particles (AuNR-HSAPs), laser 
irradiation, and dosage of the cancer-combative drug provides a trifocal approach to 
treat HCC.  This approach could be performed laparoscopically with direct injection of 
particles into tumors through probes or catheters, eliminating the need for an invasive 
surgery.  The HSAPs are naturally biocompatible and unlikely to be rejected by the 
body.  The toxicity associated with gold of the AuNRs is low.12  The photothermal 
irradiation from the laser is near-infrared (NIR) radiation readily absorbed by the AuNRs 
and converted into heat for a selective thermal ablation.8  Mammalian tissue allows for 
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this wavelength of light (808nm) to deeply penetrate it rather than absorbing it.10  The 
targeted treatment of the AuNR-HSAPs combined with the irradiation induces stress to 
the cells, which allows for the usage of a lesser effective systemic drug dosage.  A 
lowered dosage would reduce unwanted side-effects and improve safety.  Furthermore, 
when a locoregional drug is encapsulated inside of the nanoparticles, the drugs are only 
released upon particle degradation, typically after cellular ingestion.  This allows for the 
delivery of a higher dosage of drugs to the targeted site with less exposure to non-
targeted areas.  Remaining particles not ingested could circulate through the 
bloodstream harmlessly until they are removed by metabolic processes. 
Over the years, the development of functionalized nanoparticles as a selective 
therapeutic for treating cancer has been explored.  The term nanoparticle is versatile 
and can refer to any appropriately-sized particle prepared from polymers, inorganic 
compounds, protein scaffolding, etc. with each type having different advantages and 
disadvantages.  Scientists hoped to exploit exclusive properties of these particles such 
as their small size, tunable surface chemistry, drug encapsulation abilities, longer 
duration of circulation as drug-carriers, ease of cellular membrane penetration, and site-
specific targeting.24  With their dedication, many projects are in progress, while some 
have reached the stage of clinical trials on various types of cancers including, prostate, 
breast, lung cancer, and more.  The most common trials of nanoparticles used for 
cancer therapeutics involve encapsulating or conjugating drugs to the surface of the 
particles.  Some trials are testing nanoparticles with ligand functionalized surfaces, 
which serve to direct the particles to specific cells via receptors.  Other trials involve the 
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exploration of pharmaceuticals previously thought unusable due to being hindered by 
pharmacokinetic or biocompatibility issues.16  
For these nanoparticles encapsulating gold with an albumin scaffold, previous 
research has established successful synthesis protocols19 and their effectiveness in 
treating breast cancer cell lines20 and murine models of renal cell carcinoma13.  
Research using gold-conjugated albumin particles similar to AuNR-HSAPs have also 
been conducted on two immortalized HCC cell lines, HepG2 and HepB5.  The study 
showed a measure of success in eliminating cells using the method of enhanced laser 
thermal ablation, but concluded that further research was necessary.14  The same team 
also tested the gold-conjugated particles paired with the photothermal ablation on ex 
vivo-perfused liver specimens obtained from HCC patients.  They were able to show a 
considerable amount of necrosis in the tissue, which was indicative of treatment 
success.15   
In our own study, we tested the effectiveness of HSAP, AuNRs-HSAPs, and a 
combination of near-infrared irradiation, chemotherapeutic drug, and AuNR-HSAPs on 
the in vitro treatment of HCC. The patient-derived line would better reflect genomic 
modifications within patients with HCC compared to immortalized cell lines.  
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Materials and Methods 
Materials 
The Human Serum Albumin and 8% aqueous glutaraldehyde were purchased 
from Sigma Aldrich (St. Louis, MO, USA).  The ethanol (200-proof, ACS/USP grade) 
was obtained from Pharmco-AAPER (Brookfield, CT, USA).  All water was distilled, 
deionized, and nano-purified with the Barnstead Nanopure filtration system from 
ThermoFischer Scientific Inc. (Marietta, OH, USA).  All reagents used were sterile or 
were sterilized by filtration using a 0.2µm PES filter from EMD Millipore (Burlington, MA, 
USA).  Alexa Fluor™ 647 NHS Ester (Succinimidyl Ester) was purchased from 
ThermoFisher Scientific Inc. (Marietta, OH, USA). 
 The unfunctionalized bare gold nanorods were purchased from Nanopartz, Inc. 
(Loveland, CO, USA).  The rods were colloid-shaped, 10nm diameter, 40nm length, 
surface plasmon resonance (SPR) peak of 808nm, SPR absorbance OD = 1, 6.3×1011 
AuNR/mL in water containing cetyltrimethylammonium bromide (CTAB).  CTAB is an 
antiseptic capping agent toxic to cells and highly sensitive to ethanol, which causes 
particle aggregation and malformation during synthesis.  It appears as silver swirls in 
the solution at low temperatures in excess, which must be removed.  To prepare the 
AuNR solution for use, the solution was warmed briefly in a water bath to dissolve the 
CTAB into solution.  Once the silver precipitate was no longer visible, it was centrifuged 
at 15,000RPM for 5 minutes.  The supernatant was removed and saved.  The pellet was 
redispersed in nanopure water (H2O-NP).  The supernatant was centrifuged to capture 
remaining AuNRs, and the supernatant was saved once again.  Pellets were 
consolidated.  The process of centrifuging supernatants and collecting pellets was 
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repeated approximately 5 times until a pellet no longer formed.  The total volume 
remained consistent with the original starting volume to avoid diluting the AuNR 
solution. 
Human hepatic adenocarcinoma immortalized cell line SKHep1 and human HCC 
immortalized cell line Hep3B were acquired from ATCC (Manassas, VA, USA).  Patient-
derived HCC cell line TS-50.1.1 was obtained from Ochsner Medical Center (Jefferson, 
LA, USA).  Dulbecco Modified Eagle Medium (DMEM), Fetal Bovine Serum (FBS), 
QPS, Bovine Serum Albumin (BSA), B27 supplement 50x, Fibroblast Growth Factor 
(FGF), Epidermal Growth Factor (EGF), insulin, trypsin-EDTA (0.25%), Phosphate 
Buffered Saline (PBS) 1x pH7.4 were purchased from ThermoFisher Scientific Inc. 
(Marietta, OH, USA).  PolyHEMA was acquired from Sigma Aldrich (St. Louis, MO, 
USA). 
Complete media (c-DMEM) for the two immortalized hepatic cell lines was made 
by adding 10% FBS, 1% QPS, and 89% DMEM.  The preparation for the tumor-
spheroid media (TS-media) for the TS-50.1.1 cell line was adapted from Song et al. 
protocol. 23  Approximately 10mL of TS-media was prepared fresh at the time of each 
use and leftover media was discarded.  The following components were added: 93.17% 
of c-DMEM, 2% of BSA at 0.4mg/mL, 4% of B27 diluted to 2x, 0.1% of FGF diluted to 
20ng/mL, 0.1% of EGF diluted to 20ng/mL, and 0.63% of insulin diluted to 25µg/mL. 
Doxorubicin hydrochloride 98-102% (HPLC) was obtained from Sigma Aldrich 
(St. Louis, MO, USA).  CellTiter 96® Non-Radioactive Cell Proliferation (MTT) Assay 
was obtained from Promega (Fitchburg, WI, USA).  eBioscience™ Fixable Viability Dye 
eFluor™ 780 was purchased from Life Technologies (Carlsbad, CA, USA). 
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Synthesis of blank HSAPs, AF647-HSAPs, AuNR-HSAPs 
The HSAPs were synthesized via a modified desolvation technique used by 
Peralta and her team.19  The overall process is outlined in Figure 1. 
 
Figure 1.  HSAP synthesis process. 
After dissolving 2mg of solid HSA in 20µL of nanopure water, varying 
components were added to the mixture to functionalize the particles (Table 1).   
 
Table 1.  Variable components added to produce different HSAPs. 
For all types of HSAPs, 5mL of 100% ethanol was slowly added at an approximate rate 
of 1mL/min., using a variable flow peristaltic pump to denature the HSA protein.  Lastly, 
4.7µL of 8% aqueous glutaraldehyde was added to crosslink the HSA within the 
HSAP Type H2O Additional Reagents
Blank 2mL N/A
AF647 1.99mL 10µg AF647 dye dissolved in 10µL of DMSO
AuNR N/A 2mL of the pre-prepared AuNR solution
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particles.  The solution was allowed to react for at least 18 hours at room temperature in 
a closed vial to prevent evaporation before undergoing a washing process.   
To wash the particles, the solution was centrifuged at 13,000RPM for 25 minutes.  
The supernatant was discarded and 1mL of a wash solution containing a 1:3 ratio of 
water and ethanol (respectively) was added.  The pellet was resuspended in solution via 
ultrasonication.  This washing process was repeated twice.  The final pellet was 
redispersed in 1mL of c-DMEM and stored at 4°C until use. 
Microscopy 
Brightfield and fluorescence images were obtained using an Olympus IX71 
Microscope (Olympus Corporation, Tokyo, Japan) at 200x or 400x magnification. 
Dynamic light scattering (DLS) 
The diameter of the HSAPs were obtained using a Mobius dynamic light 
scattering instrument (Wyatt Technology Corporation, Santa Barbara, CA).  10µL of 
HSAP solution was diluted 1:100 with H2O-NP before injecting into the instrument. 
Transmission electron microscopy (TEM) 
Images of the HSAPs were obtained by a JEOL transmission electron 
microscope (FEI, Hillsboro, OR).  Samples were prepared on a thin film of gold lattice 
mesh to facilitate imaging. 
Ultraviolet-visible spectroscopy (UV-Vis) 
Absorbance measurements of the HSAPs were acquired with a Cary 60 
absorbance spectrometer (Agilent Technologies, Santa Clara, CA). 
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Culturing cell lines: SkHep1, Hep3B, TS-50.1.1 
The SkHep1 and Hep3B cell lines were cultured in c-DMEM at 37°C humidified 
5% CO2 atmosphere.  Cells were cultured in T-75 tissue culture ﬂasks and kept in a 
logarithmic growth pattern by routine passages, splitting upon reaching confluency. 
The TS-50.1.1 cell line was derived from a primary tumor of a patient that 
underwent a resection at Ochsner Health System. The tumor was digested and grown 
in c-DMEM.  Once a cell line was established, cells were cultured in TS-media at 37°C 
humidified 5% CO2 atmosphere adapting the protocol developed by Song et al.23  A 24-
well tissue culture plate was treated with 100µL/well of polyHEMA and left to dry 
overnight in sterile conditions.  Cells were plated in the polyHEMA-treated non-adherent 
plate.  The media was refreshed after 1 week, and cells were strained though 30µm 
strainers to enrich the population for tumor spheroid forming cells.  Strained cells were 
passed to a new non-adherent plate.  After another week, spheroids were strained 
again and transferred to grow in a T-25 tissue culture flask in c-DMEM.  Once reaching 
confluency, cells were passed into a T-75 tissue culture ﬂask and kept in a logarithmic 
growth pattern by routine passages, splitting upon reaching confluency. 
General experimental procedures 
 The experiments of this study followed a general protocol with some experiments 
requiring additional steps (Figure 2).  The general protocol can be summarized as a 4-
day plan.  Each experiment was repeated in triplicate or more with the exception of 
experiments involving the TS-50.1.1 cell line.   
10 
 
 
Figure 2.  General protocol of experiments. 
On day 1, cells are seeded into either 24- or 96-well tissue culture plates 
according to Table 2.  On day 2, media was removed and replaced with either complete 
media or experiment specific HSAP.  For TS-50.1.1, similar confluency was not 
obtained until 4 days later, delaying the process.  For day 3, media was removed, cells 
were washed with 1x PBS, and fresh media was replaced.  For some experiment, cells 
were treated with laser irradiation treatment and/or doxorubicin drug.  Day 4 was the 
endpoint in which an MTT assay or flow cytometry was performed.  All experiments 
throughout were performed in triplicate with exception to experiments involving TS 
50.1.1 cell line. 
 
Cell Line Seeding Density Cells/Well
SkHep1 8,500                                              
Hep3B 5,000                                              
TS-50 N/A
96-Well Tissue Culture Plate (0.32cm
2
/well)
11 
 
 
Table 2.  Seeding densities according to cell line and well size. 
Near-infrared (NIR) photothermal laser irradiation 
Cells with and without AuNR-HSAPs were treated with an NIR photothermal 
irradiation by laser to induce and enhance cytotoxicity.  Modelled after protocols used 
by Liu et al.13, the treatment was administered by a LabSpec 808nm collimated diode 
laser system (Laserglow Technology, Toronto, Canada).  The power was set to 
approximately 2.1W.  The laser was vertically positioned 7cm above the cells.  The size 
of the laser beam was approximately 0.5cm × 1cm. 
Laser treatment occurred on day 3 of experimental protocols. Briefly, after cells 
were washed with 1x PBS and 200µL of c-DMEM was added.  Cells were exposed to 
the thermal laser for differing amounts of time with exposure covering the entire wells in 
3 iterative sessions. Upon thermal irradiation completion, media was added to wells for 
a final volume of 1mL. 
Inhibitory concentration of doxorubicin 
 The SkHep1 and Hep3B cell lines were tested to determine the half maximal 
inhibitory concentration (IC50) of the doxorubicin drug.  General experimental protocol 
described above was used.  The range of drug dosages differed for each line and well 
size (Table 3).  Cell metabolic activity and viability was determined by MTT assay and 
flow cytometry, respectively. 
Cell Line  Seeding Density Cells/Well 
SkHep1 50,000                                            
Hep3B 30,000                                            
TS-50 30,000                                            
24-Well Tissue Culture Plate (1.9cm
2
/well)
12 
 
 
 
Table 3.  Tested doxorubicin dosages to determine IC50. 
Combinatorial treatment 
The combinatorial experiments were performed on all cell lines to determine the 
synergistic effects of the treatments.  The following conditions were tested on cells in 
each experiment: zero control; heat-kill control; AuNR-HSAP addition only; doxorubicin 
addition only; laser treatment only; AuNR-HSAP and doxorubicin additions; AuNR-
HSAP addition with laser treatment; doxorubicin addition with laser treatment; and 
AuNR-HSAP and doxorubicin additions with laser treatment.  Each experiment was 
repeated in triplicate with the exception of experiments involving the TS-50.1.1 cell line.   
The experimental protocol described above was used with doxorubicin 
concentration of 0.025µM for SkHep1, 0.05µM for Hep3B, and 0.25µM for TS-50.1.1.   
Flow cytometry 
Cellular viability and cytotoxicity were measured using a Attune NXT Flow 
Cytometer (Thermofisher, Carlsbad, CA) and staining cells using the fixable viability 
eFluor™ 780 dye according to manufacture protocol. 
Method µM µM µM µM µM µM µM µM
MTT-Assay (96-Well Plate) 0.11     0.21     0.53     1.1        2.1        N/A N/A N/A
Flow Cytometry (24-Well Plate) 0.0063 0.0125 0.025   0.05     0.1        0.25     0.5        1           
SkHep1
Method  µM  µM  µM  µM  µM  µM  µM  µM 
MTT-Assay (96-Well Plate) 0.13     0.25     0.63     1.3        2.5        N/A N/A N/A
Flow Cytometry (24-Well Plate) 0.005   0.01     0.05     0.1        0.25     0.5        0.75     1           
Hep3B
13 
 
Cell viability was determined by selecting the number of cells based on a size-
gating strategy and normalizing to the control for each experiment. 
MTT assay  
The metabolic activity of the cells was measured using an MTT assay.  MTT 
assay was performed according to manufacturer protocol. Dye solution was allowed to 
incubate for 1 hour in SkHep1 and 1 hour 20 minutes in Hep3B.  Absorbance of the 
formazan product was detected at 570nm and 650nm and recorded via xMark 
Microplate Absorbance Spectrophotometer (Bio-Rad, Hercules, CA).  The readings at 
650nm were subtracted from the readings at 570nm to remove background 
interference.  Metabolic activity was normalized against the control. 
Statistical analysis 
An ANOVA Test (statistical mean analysis) and a Dunnet’s Multiple Comparisons 
Test (statistical comparison against control) were performed on the data to produce the 
graphs.  Results were expressed as mean and its SEM (standard error of mean) relative 
to the control.  A p < 0.05 was indicative of a one-asterisk difference of statistical 
significance when compared to the control.  A p < 0.01 signified a difference of two or 
more asterisks.  Graphs were composed with GraphPad Prism 8 (GraphPad Software, 
La Jolla, CA). 
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Results and Discussion 
Blank HSAP, AF647-HSAP, AuNR-HSAP 
Each type of nanoparticles synthesized were distinguishable by their 
appearance, size, and certain properties.  Empty, unloaded, blank HSAPs were ivory-
colored, while AF647-HSAPs were blue-green-colored particles, and AuNR-HSAPs 
were pink in color. 
The sizes of HSAPs were determined using DLS and outlined in Table 4.  Blank 
HSAPs measured an average 93.6nm in radius, AF647-HSAP radius measured 
47.0nm, and the AuNR-HSAP radius averaged 49.7nm.  The sizes of the HSAPs were 
affected by the addition of compounds to be encapsulated. 
 
Table 4.  Comparison of HSAP sizes by DLS. 
A hypothesis for the decrease in size after the addition of the AF647 fluorescent 
dye compound is that the compound is interfering with the crosslinking of particles 
during synthesis.  Glutaraldehyde uses amine groups to crosslink HSA proteins into 
larger nanocomposites.  However, the Alexa Fluor 647 is also an amine-reactive 
compound.  The reaction of the dye may be leaving less free amines for the 
glutaraldehyde to use for binding, which could explain the decrease in particle size 
compared to blank HSAP.  Additionally, because the final particle size is dependent on 
numerous factors including the capping agent, trace amounts of the CTAB remaining in 
HSAP Type Radius (nm)
Blank 93.6
AF647 47.0
AuNR 49.7
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the AuNR solution could affect the size of the AuNR-HSAPs.  CTAB is also a cationic 
detergent which could be causing crosslinking interference as well.   
The findings on the size of the particles is an important factor to consider for 
several reasons.  One reason is the size difference would affect housing capacities of 
certain compounds, such as a chemotherapeutic drug, in which dosage and its 
limitations would be important.  Another reason lies in the delivery method of the 
HSAPs.  Tumors can retain nanoparticles released arterially in fenestrations between 
endothelial cells of blood vessels through a response called enhanced permeation and 
retention (EPR). 11  This allows long-circulating particles to accumulate in tumor tissues.  
If the HSAPs are sent intravenously, the size of the particles necessary to be long-
circulating and reach the targeted site must be a diameter between 30nm and 200nm11. 
 The AuNR-HSAPs were imaged by TEM to confirm successful encapsulation of 
the gold nanorods (Figure 3). 
 
Figure 3.  TEM image of AuNR-HSAP. 
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 Further evidence to support the successful encapsulation of the AuNRs in the 
nanoparticles was collected via UV-Vis spectrometer.  In Figure 4, a comparison of the 
absorbance measurements between the free AuNR solution, blank particles, and AuNR 
particles is shown.  A small peak was observed near 500nm wavelength for the free 
AuNR solution.  This peak is not present in the line representing the blank HSAPs.  
However, although the slope of the AuNR-HSAP line is similar to the blank HSAP line, 
the AuNR-HSAP line shows a small peak corresponding to that observed in the free 
AuNR solution peak.  This indicates the presence of gold nanorods in the particles of 
the AuNR-HSAPs.  
 
Figure 4.  Absorbance graph of blank HSAP, AuNR-HSAP, and AuNR solution. 
Effects of HSAPs on cellular metabolic activity and viability  
 The metabolic activity and cellular viability of the cells after the addition of the 
different types of HSAP were determined via MTT assay and flow cytometer, 
respectively.  These were important steps to establish the baseline cytotoxicity of the 
HSAPs in HCC cell lines. 
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In the graphs of Figure 5, the effects of the addition of blank HSAPs on SkHep1 
and Hep3B cell lines are shown.  Each bar represents wells with a percentage of its 
total media volume replaced by the particle-containing solution. The range of particle 
amounts added to a well included 25, 50, and 100%.  The maximum volume, 100%, 
meant the complete replacement of media with HSAP solution.  Most of the data 
showed no difference or only a slight decrease in both metabolic activity and cellular 
viability when compared to the control – no statistical difference from the control (NS – 
no significance).  Although, with the maximum addition of particles to the Hep3B cell 
line, the graph indicated a degree of statistically significant difference to the control for 
its viability. However, over 85% of cells were still viable at this most cytotoxic point.  
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Figure 5.  Metabolic activity and cellular viability of SkHep1 and Hep3B with the 
addition of blank HSAP. 
The effects of the dye-loaded AF647-HSAPs on the cell viability of SkHep1 and 
Hep3B cell lines were also explored.  When the experiments were performed in tandem 
with blank HSAPs, the observed effects of the AF647-HSAPs were nearly identical to 
those of the blank HSAPs (Figure 6) for both cell lines.  Neither had a negative effect 
on the cell viability.  Blank HSAP or dye-loaded HSAP do not cause any cytotoxic 
effects to the cells. 
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Figure 6.  Comparison of cellular viability between blank and AF647-HSAP addition to 
SkHep1 and Hep3B. 
 Lastly, the effects on metabolic activity and cytotoxicity of SkHep1 and Hep3B 
cell lines with the addition of gold-loaded AuNR-HSAPs were determined.  For 
cytotoxicity, the AuNR-HSAPs appeared to have a similar statistically insignificant effect 
as the blank HSAPs with less than 15% cellular death observed with the maximum 
amount of particle loading (Figures 17 and 18).  However, for the metabolic activity, a 
significant toll was observed (Figure 7).  With 25% of the media in the well replaced 
with the AuNR particle solution (25% of the maximum loading amount), the metabolic 
activity dropped to approximately 75% of the control for both cell lines.  As the AuNR-
HSAP loading amount increased, cellular activity decreased as well.  At the maximum 
amount of particle addition to the wells, the metabolic activity decreased to hover 
approximately between 55% and 65% for both cell lines.  Every datapoint collected in 
these experiments showed there were statistically significant differences between them 
and the control.  A cause for the decrease in metabolic activity with addition of the 
AuNR-HSAPs which is unobserved in the blank HSAPs could be due to the presence of 
the CTAB capping agent.  It is an antiseptic reagent and trace amounts could affect the 
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cells.   However, it was determined the addition of the AuNR-HSAPs had negatively 
impacted the metabolic activity of the cell without causing a significant cytotoxic effect.  
 
Figure 7.  Metabolic activity of SkHep1 and Hep3B with AuNR-HSAPs. 
In summation, all types of the nanocomposites by themselves were found to 
cause a statistically insignificant amount of cellular death in both SkHep1 and Hep3B 
cell lines.  Although the AuNR-HSAPs do appear to induce enough stress to the cells to 
negatively affect their metabolism, the cytotoxicity was still less than 15% of the control.  
Thus, moving forward, the maximum amount of particles was used in each experiment 
for utmost efficacy.  
Cellular uptake or adherence of AF647-HSAPs  
 For the AuNR-HSAPs to function effectively in conjunction with the photothermal 
effects of the laser irradiation, they must be present in or on the target cells.  If the 
nanoparticles are not ingested nor bound to the cell surface, they may be swept away 
from the treatment area, missing the target site, but also missing the photothermal 
effects of the irradiation.  Therefore, obtaining a confirmation of the uptake or adherence 
of the particles to the cells were vital.  By adding AF647-HSAPs to the wells, the cells 
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were essentially labelled with a bright far-red fluorescent dye if the particles were taken 
up into the cells or adhered onto cell surfaces.  Then, the fluorescence of the cells was 
measured by flow cytometry using a channel suited for detecting the AF647 dye. 
Initially, varying amounts of dye-loaded AF647-HSAPs were added to the wells to 
determine if a saturation point of the particles taken up into the cell or bound to the cell 
surface was reached before the maximum amount of particles were added.  The range 
of particle amounts added to a well included 25, 50, and 100%.  Again, the maximum 
volume, 100%, meant the complete replacement of media with HSAP solution.  In the 
graph of Figure 8a, the fluorescence intensity (MFI units) of the cells is depicted, with 
each bar shown as a fold over the control (0%, no particle addition).  With 25% of the 
media in the well replaced with the AF647-HSAP solution, the fluorescence readings 
saw a one-thousand-fold increase compared to the control.  With the 50% amount 
particle addition, the fluorescence readings had a two-thousand-fold increase from the 
control.  The maximum amount of particle addition produced a four-thousand-fold 
increase compared to the control.  From the linear progression of fluorescence 
measurements, it was concluded the increase in added particle amounts cause the 
SkHep1 cells to uptake or bind to its cell surface more particles.  It can also be 
concluded the saturation point for the uptake or binding of particles was not reached by 
the SkHep1 cells before the maximum amount of HSAPs were added. 
In the graph of Figure 8b, the fluorescence intensity of SkHep1 cells with no 
particle addition (0%, control), blank HSAP addition (100%, maximum amount of particle 
loading), and AF647-HSAP particle addition (100%) were compared.  Without the 
addition of any type of HSAPs, the graph of the cells show a peak at low fluorescence.  
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It also sets a baseline for the other datasets as the control group.  The cells with the 
addition of the blank HSAPs show a peak shifted to the right from the control with 
approximately a one-fold logarithmic increase in fluorescence measurements.  The 
graph of the cells with the dye-loaded AF647-HSAPs show a peak at higher 
fluorescence shifted even farther to the right with approximately a two-fold logarithmic 
increase in fluorescence reading compared to the control.  Interpreting the data of the 
graph, it was determined that the particles were present in or on the SkHep1 cells due 
to the increased fluorescence measurements caused by the dye in the AF647-HSAP.  
These results do not confirm uptake of particles by the cells (or lack thereof).  However, 
they do suggest the likelihood of uptake or surface binding of HSAPs. 
 
Figure 8a.  (Left) Fluorescence intensity of SkHep1 with various amounts of AF647-
HSAP added.  
Figure 8b.  (Right) Fluorescence intensity of SkHep1 with no particles, blank particles, 
and AF647 particles added. 
A point to note in the data represented in Figure 8b was the peak shift observed 
for the cells with the addition of the blank HSAPs.  There was an increase in 
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fluorescence readings although the blank nanoparticles contain no dyes to produce any 
fluorescence.  This is likely caused by interference from background fluorescence.  It 
was determined the particles themselves produce a bright green fluorescence similar to 
fluorescein (FITC), which has an absorption maximum at 490nm and emission 
maximum of 525nm25.  This is visualized with a fluorescence microscope at 200x 
magnification in Figure 9.  The particles were dispersed in an acidic buffer, which 
caused particles aggregation for better visualization.  Although the channel of the flow 
cytometer uses a filter set specific for red fluorescent dyes (AF647), it is possible for the 
green background fluorescence to spill over into this channel and capture the data.   
 
Figure 9.  Fluorescence microscopy image of blank HSAP dispersed in acidic buffer. 
The uptake/adherence experiments were repeated for the Hep3B cell line.  As 
shown in Figure 10a, the addition of increasing amounts of AF647-HSAPs to the wells 
resulted in a similar linear progression of fluorescence measurements.  However, 
Hep3B cells with the maximum amount of particle addition saw only an approximately 
five-hundred-fold increase compared to the control, rather than the four-thousand-fold 
increase the SkHep1 cells showed.  In the graph of Figure 10b, similar peak shifts to 
the previous experiment with SkHep1 indicative of the presence of particles in or on the 
24 
 
Hep3B cells were observed.  However, for Hep3B, the shifts were more minor with the 
AF647-HSAP peak only showing approximately a one-fold logarithmic increase in 
fluorescence measurements as opposed to the two-fold logarithmic increase seen of the 
SkHep1. 
 
Figure 10a.  (Left) Fluorescence intensity of Hep3B with various amounts of AF647-
HSAP added. 
Figure 10b.  (Right) Fluorescence intensity of Hep3B with no particles, blank particles, 
and AF647 particles added. 
For the Hep3B cell line, the overall conclusion was the same as the SkHep1 – 
particle uptake/adherence has a positive relationship with the amount of HSAPs added, 
and the particle uptake/adherence does not reach a point of saturation before the 
maximum amount of HSAPs were added.  However, it was also determined that the 
cells of the Hep3B cell line had much less interaction (whether by ingestion or 
adherence) than the SkHep1 cells.  This conclusion is depicted clearly in Figure 11 
showing the difference in MFI units detected during the experiments.  The combinatorial 
treatment is likely to be more effective with a greater amount of AuNR-HSAP uptake or 
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adherence to absorb the photothermal irradiation.  Therefore, moving forward, the 
maximum amount of particles was used in all experiments. 
 
Figure 11.  Comparison of the fluorescence intensity of SkHep1 and Hep3B with 
various amounts AF647-HSAP added. 
For the patient-derived TS-50.1.1 cell line, the experiment was repeated, but only 
testing the maximum amount of particle addition as decided after the uptake/adherence 
experiments on the two immortalized cell lines.  In Figure 12, the graph shows a slight 
shift in the peak of the cells with the AF647-HSAPs added compared to the control 
peak.  However, the shift in fluorescence measurements is even more minor than the 
shift seen in the Hep3B line, as this peak shows an approximately half-fold increase 
rather than a one- or two-fold increase. 
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Figure 12.  Fluorescence intensity of TS-50.1.1 with no particles, blank particles, and 
AF647 particles added. 
In the graph of Figure 13, the fluorescence intensity data of SkHep1, Hep3B, 
and TS-50.1.1 with maximal AF647-HSAP addition are compared to each other in MFI 
units.  While the SkHep1 hovers approximately at 4,500 MFI units, Hep3B is at around 
600 MFI, and TS-50.1.1 is at about 200 MFI.  Although much less than the immortalized 
lines, the TS-50.1.1 line does show indication of the presence of particles in or on the 
cells.  It can be concluded the patient-derived line has even less uptake/adherence of 
the HSAPs than the other lines.  This difference in the interaction between HSAPs and 
cell lines may be due to the difference in the characteristics between the cell lines. 
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Figure 13.  Comparison of the fluorescence intensity of SkHep1, Hep3B, and TS-50.1.1 
with AF647-HSAP addition. 
The three cell lines used for this study are all hepatic lines.  However, they 
display differences in cell morphology and functionality.  In terms of morphology, the 
differences can be observed through a microscope.  The images of the cells were 
visualized with a brightfield microscope at 400x magnification.  The SkHep1 cells 
typically have an elongated shape and may also have semi-long slender tendrils 
extending from the cell body (Figure 14a).  The Hep3B is rounder and more circular in 
shape with short tendrils that may extend from the body (Figure 14b).  The TS-50.1.1 
patient-derived cells have two types of cells: one type with a very stretched and 
elongated shape with long tendrils extending from the body and another cell type (tumor 
spheroid) unadhered to the flask surface and circular in shape (Figure 14c).  The 
difference in morphologies of the cell lines may affect the available surface area of the 
cells, which could potentially account for differences in particle adherence, if any. 
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Figure 14a.  (Left) Microscopy image of SkHep1. 
Figure 14b.  (Center) Microscopy image of Hep3B. 
Figure 14c.  (Right) Microscopy image of TS-50.1.1. 
The cell lines differ in terms of characteristics and functionality as well.  SkHep1 
is a hepatic adenocarcinoma line.  Although it was obtained from the fluid of a patient 
liver and considered a human hepatoma cell line, it does not have the typical properties 
of a hepatocyte, it does not express liver genes, nor does it exhibit expected liver 
functions. One major point to note is SkHep1 does not produce albumin7,9.  
Alternatively, the Hep3B cell line is an HCC line which does produce albumin as 
expected of a hepatocyte22.  Little information is known about the TS-50.1.1 HCC cell 
line as it is a new line expanded recently.  The results of the experiment in terms of 
particle uptake for SkHep1 and Hep3B align with the information on albumin production 
(unknown for TS-50.1.1).  If Hep3B cells produce albumin and SkHep1 cells do not, 
then having less uptake of particle composed of albumin by Hep3B due to inhibitory 
effects is logically reasonable. 
As mentioned, while the Hep3B line and the TS-50.1.1 line are HCC cell lines, 
the SkHep1 is an adenocarcinoma cell line.  There are differences in the doubling times 
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and growths between the lines.  While SkHep1 cells grow rapidly and double within 30 
hours6, the Hep3B cells have a longer doubling time between 40-50 hours5.  The TS-
50.1.1 line has an even longer doubling period than the immortalized cell lines that may 
exceed a week.  For SkHep1, cells would require a more rapid ingestion rate of 
metabolites from the surrounding media to facilitate aggressive growth.  The rates of 
ingestion for Hep3B would be lower due to its longer doubling time, and even more so 
for TS-50.1.1.  This could account for differences in HSAP uptake by ingestion.  The 
higher levels of fluorescence possibly indicating increased particle uptake for SkHep1 
support this hypothesis.  The lower fluorescence readings indicating less HSAP 
presence in Hep3B and TS-50.1.1 align with this hypothesis as well.  
Effects of photothermal laser irradiation treatment on cells 
 The metabolic activity and cellular viability of the cells after different durations of 
photothermal laser irradiation were determined by MTT assay and cytometry.  These 
experiments were conducted on cells without any particle addition.  The results of these 
experiments were essential steps to determine an appropriate treatment time with 
maximum duration while still causing little cytotoxic effect.  The irradiation should not be 
harmful to the cells by themselves without the combination of the AuNR-HSAP addition. 
In Figure 15, the photothermal effects on both SkHep1 and Hep3B cells for 2.5, 
5, 10, and 20 minutes are graphed as comparisons to the control (no irradiation).  For 
SkHep1, the data showed no significant difference from the control in metabolic activity 
with no more than a 20% decrease in activity for any treatment duration.  Therefore, the 
data of the cell viability should reflect similar results without significant difference.  
However, a degree of statistical difference was detected for the 20-minute treatment 
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period, the maximum irradiation duration.  Logically, the cytotoxicity should gradually 
increase with the increase in treatment duration.  However, a fluctuation is observed for 
the viability graph, which could be due to experimental error.  The incongruity between 
the 20-minute data of the metabolic activity and viability could also be due to 
experimental error.  Regardless, the cytotoxicity for SkHep1 is still relatively low at 25% 
with the maximum treatment duration.  For the Hep3B cells, the data showed significant 
degrees of statistical difference for the photothermal treatment’s effects on metabolic 
activity.  The activity decreased to approximately 70% for the 2.5-minute and 10-minute 
treatment periods, then to 60% for the maximum duration.  Although even the minimum 
treatment duration had negatively impacted the metabolic activity of the cell, the cell 
viability remained hardly affected.  With the cytotoxicity at a very low 5%, even at the 
maximum 20-minute irradiation time, there was no significant difference of cellular 
viability from the control.  For Hep3B, it was determined the photothermal laser 
treatment induced sufficient stress to the cells to inhibit metabolism without causing 
significant cellular death.  Moving forward, cells were exposed to the maximum 
treatment duration of 20 minutes for each experiment as it had relatively low levels of 
cytotoxicity for both cell lines.  
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Figure 15.  Metabolic activity and cellular viability of SkHep1 and Hep3B with the laser 
irradiation treatment. 
Inhibitory concentration of doxorubicin 
 The inhibitory concentration (IC50) of doxorubicin was explored for both SKHep1 
and Hep3B cell lines by determining cellular viability using flow cytometry.  A range of 
dosages up to 1uM was tested on cells without any particle addition.  The results of 
these IC50 experiments were used to determine an appropriate drug dosage to cause 
minimal cytotoxic effects by themselves, as the minimal dosage is safer for the patient 
recipient of the treatment. 
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Graphs of cellular viability of SkHep1 and Hep3B cell lines with the doxorubicin 
dosages compared to the control (no drug addition) are shown in Figure 16.  The 
cytotoxicity was not statistically significant initially.  Then, it increased to show a 
difference as the dosages increased for both lines.  However, the point in which a 
significant difference from the control was observed was different for the two cell lines 
indicating approximately 45% cellular death at 0.05µM in SkHep1 and 0.1µM in Hep3B.  
From that point until 1µM, the cytotoxicity increased to reach approximately 75% for 
both cell lines.  Moving forward, cells were exposed to the maximum dosage of 
doxorubicin that causes no significant cytotoxicity when compared to the control.  These 
were determined to be 0.025µM in SkHep1 and 0.05µM in Hep3B cells. 
 
Figure 16.  Cellular viability of SkHep1 and Hep3B with doxorubicin. 
Combinatorial treatment  
 Finally, the combinatorial treatment experiments were performed on all cell lines 
to determine the effectiveness of the concerted treatments, and the results were 
measured in terms of cell viability with the flow cytometer.   
In Figure 17, the results of the experiment for the SkHep1 cell line are graphed.  
Unfortunately, there was no difference statistically significant from the control (AuNR-
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HSAP addition only, listed as “Au only” in bar graph) for any of the conditions tested.  
There was little cytotoxicity observed for wells with only the individual addition of the 
AuNR-HSAP, doxorubicin (“Dox only” in bar graph), and laser irradiation treatment 
(“Laser” in bar graph).  Those results, with individual treatment methods were expected, 
as conditions optimized for efficacy without causing significant cytotoxicity were 
selected.  A 15% decrease in cellular viability from the control was observed testing the 
combination of the doxorubicin and the laser irradiation (“Dox-laser” in bar graph).  The 
11% of cellular death shown in the drug-only mostly accounts for the death seen in the 
combination of the two conditions.  These two methods operate independently of each 
other and a combination treatment was not expected to produce enhanced results.  
Similarly, for the combination testing of AuNR-HSAPs and doxorubicin (“Au-dox” in bar 
graph), 19% cellular death was observed.  The 9% death seen in the AuNR-HSAP only 
condition and the 11% death seen in the doxorubicin only condition mathematically 
accounts for the approximately 20% cellular death observed in the combination.  Again, 
these methods operate independently of one another and the results were expected.  
However, for the combination of the AuNR-HSAPs and the laser treatment (“Au-laser” in 
bar graph), anticipated results included an exponential increase in cellular death 
because the two methods combined should have operated synergistically to induce 
greater effects.  Instead, the observed result was a lackluster cell death of only 13%.  
For the combination of all three conditions (“Au-dox-laser” in bar graph), our hypothesis 
was that the combination of metabolic stress attributed by the AuNR-HSAPs, combined 
with the cytotoxic effects of doxorubicin and heating of the AuNR-HSAPs would be large 
enough to cause massive cellular death.  However, with the AuNR-HSAP and laser 
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combination condition was unsuccessful in causing a significant level of cytotoxicity as a 
loss in viability was only at 19%, similar to the combination of the AuNR-HSAP and 
doxorubicin. 
 
Figure 17.  Comparison of cellular viability of SkHep1 with controls and combinatorial 
treatments. 
 The data from the same combinatorial experiment performed on the Hep3B cell 
line was graphed (Figure 18).  As with the previous experiment, there was no statistical 
difference from the control in the testing of any condition.  In the combination of the 
doxorubicin and laser treatment tested, a 29% cellular death was observed.  However, 
much of the damage is attributed to doxorubicin (testing the doxorubicin by itself caused 
18% cell death), but the laser does appear to add to the stress on the cell to enhance 
cytotoxicity (testing the irradiation treatment by itself caused no cell death).  The results 
of the combination of the aforementioned AuNR-HSAP with laser treatment was similar 
to those obtained for SkHep1; it was not as effective as anticipated with only 9% cellular 
death.  The cytotoxicity of the AuNR-HSAP/irradiation combination was mostly 
attributed to the addition of the AuNR-HSAPs (testing the particles by themselves 
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yielded 5% cell death), and it was enhanced only by 4% from the combined 
photothermal treatment.  This likely reduced the synergistic effectiveness of the final 
three-pronged combinatorial test, which showed a 36% cellular death. 
 
Figure 18.  Comparison of cellular viability of Hep3B with controls and combinatorial 
treatments. 
 The combinatorial experiment was performed on a patient-derived cell line, TS-
50.1.1 (Figure 19).  However, this experiment could not be performed in triplicate as the 
growth rate of these cells were slow and a sufficient number of cells for the experiments 
could not be cultured in time.  Without repetition, the results of the experiment could 
neither be averaged nor checked for consistency.  Consequently, the results must be 
treated as preliminary. 
 Preliminary findings show no statistical difference from the control for any of the 
conditions tested.  The TS-50.1.1 cell line may show a greater cytotoxicity reaction 
(20% cell death) to the addition of AuNR-HSAPs than the immortalized cell lines.  
However, that level of cytotoxic effect is not observed in any of the other tests involving 
the addition of AuNR-HSAPs.  In fact, the data was found to be conflicting with the 
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AuNR-HSAP/doxorubicin showing 0% cell death, AuNR-HSAP/laser treatment showing  
7% death, and the AuNR-HSAP/doxorubicin/laser treatment showing only 3% cellular 
death.  The 20% cell death found in the testing of the AuNR-HSAP addition by itself 
could be attributed to an experimental error or anomaly.  Repeat experiments must be 
conducted to confirm.  Again, the results of the combination of the AuNR-HSAP 
addition, with the photothermal treatment to the cells exhibited no synergistic effects as 
anticipated.  The final combinatorial test involving all three variables showed an even 
less efficient 3% cellular death.  Overall, the data from the single TS-50.1.1 
combinatorial experiment was conflicting, inconsistent, and likely unreliable.  The 
experiment must be repeated. 
 
Figure 19.  Comparison of cellular viability of TS-50.1.1 with controls and combinatorial 
treatments. 
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Conclusion 
After repeating the experiments of this study to produce consistent results in 
triplicate, the inefficacy of the combination of the AuNR-HSAPs treated with the 
photothermal laser irradiation must be addressed.  According to the research of Liu et. 
al13, renal carcinoma epithelial cells did show indications of uptake and the AuNR-
HSAPs combined with the photothermal treatment were effective in treating a tumor of 
the kidney.  From the study outlined in this thesis, the results from the MTT assay and 
flow cytometry suggest a difference in the level of interaction with the particles, whether 
by surface binding or uptake, for each cell line.  An overall low adherence or uptake of 
the HSAPs for the hepatocytes could be possible, and it may be the issue causing the 
inefficacy.  This hypothesis could be explored with the expansion to different types of 
cells.  It could be that this alternative treatment using HSAPs is more effective for 
certain organs than others and will be used for those specific cancers rather than a 
broad overall treatment encompassing all cancers.  However, another direction of the 
research could move towards using specific antibodies affixed to the particles to bind to 
cell surface receptors for targeted binding specific to hepatocytes.  Many pathways are 
available for exploration. 
If the limitation of the AuNR-HSAPs combined with the photothermal treatment 
could be overcome, the next steps for this study would be to load the particles with both 
AuNR and the doxorubicin drug.  The experiments should be tested in vitro once again, 
but then eventually moving on towards in vivo models. 
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